Rani Therapeutics Holdings (RANI) Liabilities and Shareholders Equity (2020 - 2026)

Rani Therapeutics Holdings' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $51.9 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 115.04% year-over-year to $51.9 million in Q1 2026; TTM through Mar 2026 was $137.5 million, a 7.09% decrease from a year earlier, with the FY2025 full-year figure at $58.6 million, up 60.02% from the prior year.
• Liabilities and Shareholders Equity slipped to $51.9 million in Q1 2026 per RANI's latest filing, from $58.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $115.3 million in Q1 2022 and bottomed at $10.1 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $57.9 million (2023), against an average of $63.7 million.
• Across the five-year window, Liabilities and Shareholders Equity slumped 76.71% in 2025 and soared 115.04% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $108.0 million in 2022, then slumped by 46.39% to $57.9 million in 2023, then tumbled by 36.75% to $36.6 million in 2024, then soared by 60.02% to $58.6 million in 2025, then slipped by 11.5% to $51.9 million in 2026.
• Per Business Quant, the three latest RANI Liabilities and Shareholders Equity figures stand at $51.9 million (Q1 2026), $58.6 million (Q4 2025), and $10.1 million (Q3 2025).